Table I.
Patient characteristics
| Parameter | Baseline population N = 384 |
|---|---|
| Age, years, mean ± SD | 53.9 ± 13.8 |
| Sex; Male, n (%) | 255 (66.4) |
| Employment status, n (%) Employed (full-time, part-time, student, and sick-leave) Unemployed Retired |
75 (19.5) 162 (42.2) 147 (38.3) |
| Diagnosis of condition leading to upper limb spasticity, n (%) Acquired brain injury (stroke/trauma/other) Spinal cord injury Other |
374 (97.4) 8 (2.1) 2 (0.5) |
| Aetiology, n (%) Vascular (infarct or haemorrhage) Trauma Hypoxic Inflammatory Tumour Degenerative Other |
328 (85.4) 44 (11.5) 1 (0.3) 5 (1.3) 2 (0.5) 2 (0.5) 2 (0.5) |
| Affected leg, n (%) Left Right |
219 (57.0) 165 (43.0) |
| Affected by upper limb spasticity, n (%) Dominant arm Non-dominant arm Both No |
156 (47.6) 170 (51.8) 2 (0.6) 56 (14.6) |
| Time since onset of the event leading to lower limb spasticity, years Mean ± SD Median (IQR) |
6.9 ± 7.9 4.7 (1.7, 8.6) |
| Prior BoNT treatment; n (%) BoNT naïve Previously treated |
96 (24.0) 288 (76.0) |
| Time interval between onset of event and first BoNT injection, years Mean ± SD Median (IQR) |
N = 309 3.6 ± 6.9 1.3 (0.6, 3.3) |
SD: standard deviation; IQR: interquartile range; BoNT: botulinum toxin type A.